NEW YORK, February 27, 2017 /PRNewswire/ --
Four US Biotech equities have been lined up by Stock-Callers.com for evaluation today, and they are: Anthera Pharmaceuticals Inc. (NASDAQ: ANTH), Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR), Pacific Biosciences of California Inc. (NASDAQ: PACB), and Conatus Pharmaceuticals Inc. (NASDAQ: CNAT). According to an article on ETF Trends, market observers are growing more bullish on the sector as a Republican-led Congress and administration could enact reforms to free cash held overseas for tax reason by large US pharmaceutical companies, which could pave the way for increased acquisitions in the sector. These stocks research reports can be downloaded now by simply registering for free at:
Hayward, California headquartered Anthera Pharmaceuticals Inc.'s shares rose 0.58%, finishing last Friday's session at $0.69, with a total trading volume of 884,859 shares. Over the last month and since the start of this year, the stock has advanced 34.89% and 6.96%, respectively. The Company's shares are trading below their 50-day moving average by 23.90%. Additionally, shares of Anthera Pharma, which focuses on the development and commercialization of medicines for patients with unmet medical needs, have a Relative Strength Index (RSI) of 39.20.
As per a SEC filing dated February 16th, 2017, Anthera Pharma received a letter from the Listing Qualifications Staff of The NASDAQ Stock Market on February 10th, 2017, informing the Company that for the last 30 consecutive business days, the bid price of Anthera's common stock has closed below the minimum $1.00 per share requirement for continued inclusion under Nasdaq Listing Rule 5450(a)(1). The letter stated that NASDAQ will provide Anthera Pharma a grace period of 180 calendar days, or until August 09th, 2017, to regain compliance. Your complete research report on ANTH can be retrieved for free at:
On Friday, shares in Pasadena, California headquartered Arrowhead Pharmaceuticals Inc. ended the session 1.42% higher at $2.15. The stock recorded a trading volume of 423,754 shares. The Company's shares have gained 17.49% in the last month and 38.71% on an YTD basis. The stock is trading above its 50-day moving average by 20.91%. Moreover, shares of Arrowhead Pharma, which develops novel drugs to treat intractable diseases in the US, have an RSI of 61.63.
On February 06th, 2017, Arrowhead reported revenue of $43.65 million for Q1 FY17, compared to revenue of $43.75 thousand for Q1 FY16. The Company posted net loss of $120.86 million, or $0.17 per share, for Q1 FY17 compared to net loss of $192.64 million, or $0.32 per share, for Q1 FY16. A free report on ARWR is just a click away at:
Pacific Biosciences of California
Menlo Park, California headquartered Pacific Biosciences of California Inc.'s stock climbed 0.79%, to close the day at $5.12, with a total trading volume of 822,250 shares. The Company's shares have advanced 3.85% in the last one month and 34.74% on an YTD basis. The stock is trading 7.15% above its 50-day moving average. Additionally, shares of Pacific Biosciences of California, which designs, develops, and manufactures sequencing systems to resolve genetically complex problems, have an RSI of 57.24.
On February 02nd, 2017, Pacific Biosciences announced that revenue for Q4 2016 totaled $25.7 million, compared to $36.3 million for Q4 2015. The Company's Product and service revenue for Q4 2016 increased 92.2% to $24.4 million, compared to $12.7 million for Q4 2015. Pacific Biosciences' gross profit for Q4 2016 was $11.4 million, resulting in a gross margin of 44.2%, compared to gross profit of $26.5 million and a gross margin of 72.9%, respectively, for Q4 2015. The Company's net loss for Q4 2016 was $19.0 million, compared to a net loss of $1.4 million for Q4 2015. Sign up for your complimentary research report on PACB at:
Shares in San Diego, California headquartered Conatus Pharmaceuticals Inc. recorded a trading volume of 130,754 shares. The stock ended at $4.95, rising 2.70% from the last trading session. The Company's shares have gained 11.49% in the past month and 164.71% over the previous three months. The stock is trading above its 50-day and 200-day moving averages by 9.90% and 87.66%, respectively. Furthermore, shares of Conatus Pharma, which focuses on the development and commercialization of novel medicines to treat liver diseases in the US, have an RSI of 53.52.
On February 07th, 2017, Conatus Pharma announced the appointment of William R. LaRue as an additional independent member to Conatus Pharma's Board of Directors. Mr. LaRue also will serve as Chair of the Audit Committee. Mr. LaRue currently serves as a member of Tracon Pharmaceuticals, Inc.'s Board of Directors and Chair of the Audit Committee, and as a member of Applied Proteomics' Board of Directors and Chair of Audit Committee. Register for free on Stock-Callers.com and download the latest research report on CNAT at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA